Chloroquine Administration in Breastfeeding Mothers Associates with Increased HIV-1 Plasma Viral Loads
Authors & affiliation
William A Paxton, Marloes A Naarding, Ferdinand WNM Wit, Nienke J Veldhuijzen, Matthew Chersich, Brigitte Kankindi, Rene A Douma, Samuel Tuyizere, Suzanne Jurriaans, Rolf W Sparidans, Jos H Beijnen, Georgios Pollakis, Johan R Boelaert, Joep MA Lange, Joseph Vyankandondera, Stanley Lüchters
Abstract
2Abstract Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been proposed to be effective at treating COVID-19 patients. We, and others, have previously reported on the capacity of CQ to reduce HIV-1 replication in vitro. We tested CQ administration in post-partum mothers on influencing HIV-1 viral loads in human milk as a means of lowering mother to child transmission. A Phase I/II, randomized, placebo-controlled study to evaluate chloroquine administration to reduce HIV-1 RNA levels in human milk: the CHARGE study. Thirty HIV-1 positive pregnant Rwandese women (CQ n = 20; placebo n = 10) were enrolled in a 16-week study, with the treatment group receiving a 200 mg oral dose of CQ daily. Base-line plasma viral load (pVL) measurements and CD4 counts were determined prior to delivery, and pVL, breast milk VL (bmVL) and CQ levels measured during treatment. For women receiving treatment, CQ concentration was higher in breast milk compared to plasma (over 2.5-fold), with a positive correlation between the levels in the two compartments (P < 0.003). A link between high CQ concentrations in plasma and high CD4 counts (P < 0.001) was observed. Surprisingly, we found a significant increase in pVL after CQ treatment in over half of the mothers (n=11; P < 0.001) and with no alteration to bmVL measurements. No specific amino acid alterations in the gp120 envelope sequences could be associated with CQ administration. CQ usage is associated with a significant increase to pVL in early breastfeeding mothers from Rwanda which cautions against the use of CQ in such individuals. Our results highlight a discrepancy between CQ effects on modulating HIV-1 replication in vitro versus in vivo and indicate caution when prescribing CQ to post-partum HIV-1 untreated mothers. This discrepancy should be taken into consideration when testing CQ or HCQ treatment in COVID-19 clinical trials, especially relating to the post-partum setting.
Publication date:
2020
Staff members:
Link to publication
Attachments
2020.04.29.20085308v2.full.pdf (open)Related publications
Stanley Lüchters, Davy Vanden Broeck, Matthew Chersich, Annalene Nel, Wim Delva, Kishor Mandaliya, Christophe Depuydt, Patricia Claeys, John-Paul Bogers, Marleen Temmerman
2022 Increased condom use among key populations using oral PrEP in Kenya : results from large scale programmatic surveillanceGriffins Manguro, Abednego M. Musau, Daniel K. Were, Soud Tengah, Brian Wakhutu, Jason Reed, Marya Plotkin, Stanley Lüchters, Peter Gichangi, Marleen Temmerman
2018 Opportunities for linking research to policy : lessons learned from implementation research in sexual and reproductive health within the ANSER networkEmilomo Ogbe, Dirk Van Braeckel, Marleen Temmerman, Elin C Larsson, Ines Keygnaert, Wilson De los Reyes Aragón, Feng Cheng, Gunta Lazdane, Diane Cooper, Simukai Shamu, Peter Gichangi, Sónia Dias, Hazel Barrett, Anne Nobels, Kaiyan Pei, Anna Galle, Tammary Esho, Lucia Knight, Hanani Tabana, Olivier Degomme